Aslan Pharmaceuticals Ltd.
13F holders, Q2 2024 (June 30)At the end of Q2 2024, 19 institutions reported holding Aslan Pharmaceuticals Ltd. in their 13F filings, down 3 from Q1 2024. 3 opened new positions and 5 sold out. The largest holders were BVF Inc. ($315K), Velan Capital Investment Management LP ($188K) and Shay Capital LLC ($120K). 3 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio), Ken Griffin (0.0% of Citadel Advisors's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Aslan Pharmaceuticals Ltd.
- CUSIP
- 04522R200
- Latest filing quarter
- Q2 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $15K |
| Exits | 5 | $83K |
All 13F filers, Q1 2024 → Q2 2024: 109,089 shares bought and 185,087 shares sold, net −75,998 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 19 holders
| BVF Inc. | 0.01% | No change | 1,049,999 | $315K |
| Velan Capital Investment Management LP | 0.11% | No change | 625,000 | $188K |
| Shay Capital LLC | 0.03% | No change | 400,000 | $120K |
| Sio Capital Management, LLC | 0.03% | No change | 254,150 | $76K |
| Renaissance Technologies | 0.00% | Add +13.3% | 138,860 | $42K |
| Schonfeld Strategic Advisors LLC | 0.00% | Reduce -15.7% | 124,300 | $37K |
| Citadel Advisors | 0.00% | Add +21.8% | 117,675 | $35K |
| Marex Group Ltd | 0.00% | Add +0.1% | 83,464 | $25K |
| Millennium Management | 0.00% | Add +17.0% | 46,366 | $14K |
| Two Sigma Securities, LLC | 0.00% | New | 32,213 | $10K |
| Onyx Bridge Wealth Group LLC | 0.00% | No change | 22,727 | $7K |
| Waterfront Wealth Inc. | 0.00% | Add +9.7% | 22,722 | $7K |
| UBS Group AG | 0.00% | New | 16,444 | $5K |
| Bank of America Corp. | 0.00% | Add +360.7% | 13,988 | $4K |
| XTX Topco Ltd | 0.00% | Add +11.9% | 13,811 | $4K |
| Morgan Stanley | 0.00% | No change | 8,700 | $3K |
| Rhumbline Advisers | 0.00% | No change | 1,294 | $388 |
| Qube Research & Technologies Ltd | 0.00% | No change | 34 | $10 |
| Simplex Trading, LLC | 0.00% | New | 1,762 | $0 |
"% of holder's portfolio" is ASLAN PHARMACEUTICALS LTD's weight in each manager's 13F, not the share of Aslan Pharmaceuticals Ltd. the manager owns.